Holen Sie sich die Stockscreener-App
2.4041
6.44%
0.0841
Schlusskurs vom Vortag:
$2.32
Offen:
$2.33
24-Stunden-Volumen:
25,182
Relative Volume:
0.02
Marktkapitalisierung:
$20.21M
Einnahmen:
$34.75M
Nettoeinkommen (Verlust:
$-24.76M
KGV:
-0.2003
EPS:
-12
Netto-Cashflow:
$-50.91M
1W Leistung:
+1.20%
1M Leistung:
-11.49%
6M Leistung:
-71.54%
1J Leistung:
-95.67%
1-Tages-Spanne:
$2.30
$2.44
1-Wochen-Bereich:
$2.30
$2.56
52-Wochen-Spanne:
$2.15
$57.25
Allurion Technologies Inc Stock (ALUR) Company Profile
Firmenname
Allurion Technologies Inc
Sektor
Branche
Telefon
508-647-4000
Adresse
11 HURON DR STE 200, NATICK
Vergleichen Sie ALUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.4041 | 20.21M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
132.79 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.44 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
375.00 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.11 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.37 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-02 | Eingeleitet | TD Cowen | Buy |
| 2024-09-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-02-09 | Eingeleitet | Jefferies | Buy |
Allurion Technologies Inc Aktie (ALUR) Neueste Nachrichten
Major Weight Loss Breakthrough: 20,000 Patient Study Reveals Muscle-Preserving Success of Allurion Program - Stock Titan
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS - New Castle News
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Down 42.4% in May - Defense World
(ALUR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Allurion Technologies (NYSE:ALUR) Trading 2.1% Higher – Time to Buy? - Defense World
Allurion at Jefferies Conference: Strategic US Market Entry By Investing.com - Investing.com South Africa
Allurion at Jefferies Conference: Strategic US Market Entry - Investing.com Australia
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - The Globe and Mail
Allurion to Present at Jefferies Global Healthcare Conference - BioSpace
When the Price of (ALUR) Talks, People Listen - news.stocktradersdaily.com
ALURALLURION TECHNOLOGIES INC Latest Stock News & Market Updates - Stock Titan
Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results - MSN
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program - BioSpace
Allurion Weight Loss Program Builds Muscle Mass 6.6%, Cuts Fat 11% in Clinical Study | ALUR Stock News - Stock Titan
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
4 Medical Product Stocks to Watch From a Challenging Industry - Yahoo Finance
Trend Tracker for (ALUR) - news.stocktradersdaily.com
Research Analysts Offer Predictions for ALUR FY2025 Earnings - Defense World
Yale University's Strategic Exit from Allurion Technologies Inc: A 13F Filing Insight - GuruFocus
Allurion Technologies Earnings Call: Transition and Growth - TipRanks
Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025 - MSN
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates - MSN
Allurion Technologies Inc (ALUR) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Allurion Technologies Reports Q1 2025 Financial Results - TipRanks
Allurion Technologies (ALUR) Unveils Promising Obesity Treatment Results | ALUR Stock News - GuruFocus
Allurion Technologies (ALUR) Q1 2025 Results Highlight Revenue a - GuruFocus
Transcript : Allurion Technologies Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
What To Expect From Allurion Technologies Inc (ALUR) Q1 2025 Ear - GuruFocus
Allurion To File Final Module Of Weight Loss Balloon To FDA For Approval Next Month - Nasdaq
Allurion Technologies (ALUR) Surges Over 50% Following Data Pres - GuruFocus
Earnings call transcript: Allurion Technologies Q1 2025 sees revenue drop, stock surges - Investing.com
Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript - MSN
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Prom - GuruFocus
Allurion Technologies Q1 2025 Financial Results - TradingView
ALUR Reports Q1 Revenue Exceeding Expectations, Anticipates Promising Year | ALUR Stock News - GuruFocus
Allurion Technologies reports Q1 EPS 20c vs. ($2.78) last year - TipRanks
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
After-Market Rally For Allurion (ALUR) As New Data Sparks Investor Optimism - Stocks Telegraph
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss - 01net
Allurion reports weight loss breakthrough at obesity congress - Investing.com Australia
Allurion reports weight loss breakthrough at obesity congress By Investing.com - Investing.com Nigeria
New Clinical Data: Allurion's Swallowable Balloon Supercharges GLP-1 Weight Loss Results, Preserves Muscle - Stock Titan
Finanzdaten der Allurion Technologies Inc-Aktie (ALUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Allurion Technologies Inc-Aktie (ALUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gaur Shantanu | Chief Executive Officer |
Mar 28 '25 |
Buy |
3.35 |
8,000 |
26,800 |
8,000 |
0.42%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):